Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 (Enrollment)

Exp Date

Year End 2020

Amp Volatility Score


Catalyst Info & Data Links


  • UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin in Phase 2b development for the treatment of low-grade intermediate risk non-muscle invasive bladder cancer. Utilizing the RTGel Technology Platform, UroGen’s proprietary sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter. The Company completed enrollment in the Phase 2b OPTIMA II trial in September 2019 and intends to advance the program to a pivotal study to further investigate UGN-102 in the treatment of this condition.



Updated by HC

URGN, UGN-102, NMIBC, cancer, bladder cancer, oncology

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

URGN - Complete & Durable Resp...

Summary: 65% Complete Response Rate at Three Months Duration of Response Estimated to be 72.5% at Nine Months (12-Months from Initiation of Therapy) by Kaplan-Meier Method; Median Duration of Response...

URGN - UroGen Pharma Reports T...

Summary: Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3 ATLAS Trial by Year End Achieved Jelmyto® Net Product Revenue of $3.5 Million i...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon